论文部分内容阅读
白细胞介素-2是活化T淋巴细胞的分泌产物,作用之一是激活淋巴细胞,使之转变为“淋巴因子激活的杀伤细胞(LAK)”,进而杀伤肿瘤细胞。许多资料已显示了白细胞介素-2和细胞毒性淋巴细胞在肿瘤病人治疗中的作用。本文旨在确定卵巢癌病人的淋巴细胞在体外接受重组白细胞介素-2(rIL-2)的适宜刺激后能否转变为LAK细胞,以提供应用rIL-2治疗卵巢癌病人的依据。由42例卵巢癌病人于剖腹探查术中或术后采集外周血标本,经Ficoll密度梯度离心得到单个核细胞做为效应细胞。靶细胞包括NK敏感的K562,对NK有抗性的卵巢癌细胞系PA-1、SKOV-3、SR-
Interleukin-2 is a secreted product of activated T lymphocytes. One of the functions of activating interleukin-2 is to activate lymphocytes and transform them into “lymphokine activated killer cells (LAKs)”, which in turn kill tumor cells. Numerous data have shown the role of interleukin-2 and cytotoxic lymphocytes in the treatment of cancer patients. The aim of this study was to determine whether lymphocytes from patients with ovarian cancer can be transformed into LAK cells after receiving appropriate in vitro stimulation of recombinant interleukin-2 (rIL-2) to provide evidence for the use of rIL-2 in the treatment of patients with ovarian cancer. Peripheral blood samples were collected from 42 patients with ovarian cancer during or after laparotomy. Mononuclear cells were obtained as effector cells by Ficoll density gradient centrifugation. Target cells include NK-sensitive K562, NK-resistant ovarian cancer cell lines PA-1, SKOV-3, SR-